Stockreport

EISAI TO PRESENT DATA ON LECANEMAB and OTHER ALZHEIMER'S DISEASE RESEARCH AT THE AD/PD™ 2024 ANNUAL MEETING [Yahoo! Finance]

SYSMEX CORP UNSP/ASDR  (SSMXY) 
NASDAQ:AMEX Investor Relations: sysmex.co.jp/en/ir/index.html
PDF latest findings on lecanemab (U.S. brand name: LEQEMBI ® ), Eisai's anti-amyloid beta (Aß) protofibril* antibody for the treatment of Alzheimer's disease (AD), at the 20 [Read more]